Announcements Trials
Browse Landscape

Phase

Phase NA 19Phase 2 4Phase EARLY_PHASE1 1Phase 3 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 39Glioblastoma 37Glioma 34Prostatic Neoplasms 32Neoplasms 28Multiple Myeloma 26Pancreatic Neoplasms 24Brain Neoplasms 23Colorectal Neoplasms 19Recurrence 18Squamous Cell Carcinoma of Head and Neck 16Melanoma 16Lymphoma 15Lung Neoplasms 15Neoplasm Metastasis 14Sarcoma 13Lymphoma, B-Cell 13Carcinoma, Non-Small-Cell Lung 13Triple Negative Breast Neoplasms 12Leukemia, Myeloid, Acute 12Hematologic Neoplasms 12Head and Neck Neoplasms 12Advanced Solid Tumors 10Stomach Neoplasms 9Ovarian Neoplasms 9Skin Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Neuroblastoma 8Lymphoma, Non-Hodgkin 8Colonic Neoplasms 8

Interventions

Lisinopril 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Radiation Injuries × 1 year × Clear all
NCT05530655 2026-01-13

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

University of Rochester

Phase EARLY_PHASE1 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms, Radiation Injuries

Data powered by HemOnc (CC BY 4.0) Colophon âš¡